Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up

Thanh N. Nguyen; Muhammad M. Qureshi; SVIN Global COVID-19 SAH Registry; Piers Klein; Hiroshi Yamagami; Robert Mikulik; Nima Etminan; Mohamad Abdalkader; Ossama Yassin Mansour; Anna Czlonkowska; Hannah Lo; Anvitha Sathya; Jelle Demeestere; Georgios Tsivgoulis; Nobuyuki Sakai; Petra Sedova; Espen Saxhaug Kristoffersen; Mahmoud Mohammaden; Virginia Pujol Lereis; Sergio Daniel Scollo; Alice Ma; Aminur Rahman; Thomas Bonnet; Jeroen Cortier; Sylvie De Raedt; Robin Lemmens; Noemie Ligot; Raquel C.T. Hidalgo; Daissy Liliana Mora Cuervo; Luciana De Oliveira Neves; Marco Tulio Salles Rezende; Igor Bessa Santiago; Alexander Sirakov; Stanimir Sirakov; Elena Adela Cora; Michael E. Kelly; Pascale Lavoie; Lissa Peeling; Aleksandra Pikula; Rodrigo Rivera; Hui Sheng Chen; Yimin Chen; Hongliang Fang; Marina Roje Bedekovic; Hrvoje Budincevic; J. J. Strossmayer; Martin Čabal; Emanuela Hrabanovska; Lubomir Jurak; Diederik Dippel; Leon Rinkel

doi:10.1136/jnnp-2022-329200

Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up

Thanh N. Nguyen^*, Muhammad M. Qureshi, SVIN Global COVID-19 SAH Registry, Piers Klein, Hiroshi Yamagami, Robert Mikulik, Nima Etminan, Mohamad Abdalkader, Ossama Yassin Mansour, Anna Czlonkowska, Hannah Lo, Anvitha Sathya, Jelle Demeestere, Georgios Tsivgoulis, Nobuyuki Sakai, Petra Sedova, Espen Saxhaug Kristoffersen, Mahmoud Mohammaden, Virginia Pujol Lereis, Sergio Daniel ScolloAlice Ma, Aminur Rahman, Thomas Bonnet, Jeroen Cortier, Sylvie De Raedt, Robin Lemmens, Noemie Ligot, Raquel C.T. Hidalgo, Daissy Liliana Mora Cuervo, Luciana De Oliveira Neves, Marco Tulio Salles Rezende, Igor Bessa Santiago, Alexander Sirakov, Stanimir Sirakov, Elena Adela Cora, Michael E. Kelly, Pascale Lavoie, Lissa Peeling, Aleksandra Pikula, Rodrigo Rivera, Hui Sheng Chen, Yimin Chen, Hongliang Fang, Marina Roje Bedekovic, Hrvoje Budincevic, J. J. Strossmayer, Martin Čabal, Emanuela Hrabanovska, Lubomir Jurak, Diederik Dippel, Leon Rinkel

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Article › Academic › peer-review

19 Citations (Scopus)

Abstract

Background Prior studies indicated a decrease in the incidences of aneurysmal subarachnoid haemorrhage (aSAH) during the early stages of the COVID-19 pandemic. We evaluated differences in the incidence, severity of aSAH presentation, and ruptured aneurysm treatment modality during the first year of the COVID-19 pandemic compared with the preceding year. Methods We conducted a cross-sectional study including 49 countries and 187 centres. We recorded volumes for COVID-19 hospitalisations, aSAH hospitalisations, Hunt-Hess grade, coiling, clipping and aSAH in-hospital mortality. Diagnoses were identified by International Classification of Diseases, 10th Revision, codes or stroke databases from January 2019 to May 2021. Results Over the study period, there were 16 247 aSAH admissions, 344 491 COVID-19 admissions, 8300 ruptured aneurysm coiling and 4240 ruptured aneurysm clipping procedures. Declines were observed in aSAH admissions (-6.4% (95% CI-7.0% to-5.8%), p=0.0001) during the first year of the pandemic compared with the prior year, most pronounced in high-volume SAH and high-volume COVID-19 hospitals. There was a trend towards a decline in mild and moderate presentations of subarachnoid haemorrhage (SAH) (mild:-5% (95% CI-5.9% to-4.3%), p=0.06; moderate:-8.3% (95% CI-10.2% to-6.7%), p=0.06) but no difference in higher SAH severity. The ruptured aneurysm clipping rate remained unchanged (30.7% vs 31.2%, p=0.58), whereas ruptured aneurysm coiling increased (53.97% vs 56.5%, p=0.009). There was no difference in aSAH in-hospital mortality rate (19.1% vs 20.1%, p=0.12). Conclusion During the first year of the pandemic, there was a decrease in aSAH admissions volume, driven by a decrease in mild to moderate presentation of aSAH. There was an increase in the ruptured aneurysm coiling rate but neither change in the ruptured aneurysm clipping rate nor change in aSAH in-hospital mortality. Trial registration number NCT04934020.

Original language	English
Pages (from-to)	1028-1038
Number of pages	11
Journal	Journal of Neurology, Neurosurgery and Psychiatry
Volume	93
Issue number	10
DOIs	https://doi.org/10.1136/jnnp-2022-329200
Publication status	Published - 1 Oct 2022

Bibliographical note

Funding Information:
These coauthors have the following funding: support by STROCZECH within CZECRIN Large Research Infrastructure (number LM2018128) funded by the state budget of the Czech Republic. FNUSA: PS, RM, NCB and JR; lFN Hradec Králové: RH; FESO, FEANNemocnice Jihlava: OS; Hornická Nemocnice, a.s.: HP; Nemocnice Liberec: LJ; Nemocnice Na Homolce: MK; Vojenská Nemocnice Praha: MS, FP reported royalties from Springer Nature Publishing Group and Elsevier, Research Grant from Transilvania University Brasov, speaker fees and honoraria from International Parkinson and Movement Disorders Society, AbbVie, outside the submitted work. RM was supported by project number CA18118, IRENE COST Action funded by COST Association, by the IRIS-TEPUS project number LTC20051 from the INTER-EXCELLENCE INTER-COST Program of the Ministry of Education, Youth and Sports of the Czech Republic and by STROCZECH within CZECRIN Large Research Infrastructure number LM2018128 funded by the state budget of the Czech Republic. TNN reports research support from Medtronic and the Society of Vascular and Interventional Neurology. RGN reported consulting fees for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Hybernia, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby and Synchron and stock options for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, RapidPulse and Perfuze; and investments in Viz-AI, Perfuze, Cerebrotech, Reist/Q’Apel Medical, Truvic and Viseon. AP is a consultant for Cerenovus, CereVasc, Merit and Medtronic; received research grants from Medtronic. Stocks in InNeuroCo, Galaxy, Agile, Perfuze and NTI. HY reported research grants from Bristol-Myers Squibb, lecturer’s fees from Bayer, Daiichi-Sankyo and Stryker, and membership in the advisory boards for Daiichi-Sankyo outside the submitted work. Dr. Siegler reports speakers bureau from AstraZeneca, consulting fees from Ceribell.

Funding Information:
The study was funded by the Society of Vascular and Interventional Neurology research pilot grant.

Publisher Copyright:
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/jnnp-2022-329200

Cite this

Nguyen, T. N., Qureshi, M. M., SVIN Global COVID-19 SAH Registry, Klein, P., Yamagami, H., Mikulik, R., Etminan, N., Abdalkader, M., Mansour, O. Y., Czlonkowska, A., Lo, H., Sathya, A., Demeestere, J., Tsivgoulis, G., Sakai, N., Sedova, P., Kristoffersen, E. S., Mohammaden, M., Lereis, V. P., ... Rinkel, L. (2022). Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up. Journal of Neurology, Neurosurgery and Psychiatry, 93(10), 1028-1038. https://doi.org/10.1136/jnnp-2022-329200

@article{5388a571a3b1451cbf76f7e9599a8673,

title = "Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up",

abstract = "Background Prior studies indicated a decrease in the incidences of aneurysmal subarachnoid haemorrhage (aSAH) during the early stages of the COVID-19 pandemic. We evaluated differences in the incidence, severity of aSAH presentation, and ruptured aneurysm treatment modality during the first year of the COVID-19 pandemic compared with the preceding year. Methods We conducted a cross-sectional study including 49 countries and 187 centres. We recorded volumes for COVID-19 hospitalisations, aSAH hospitalisations, Hunt-Hess grade, coiling, clipping and aSAH in-hospital mortality. Diagnoses were identified by International Classification of Diseases, 10th Revision, codes or stroke databases from January 2019 to May 2021. Results Over the study period, there were 16 247 aSAH admissions, 344 491 COVID-19 admissions, 8300 ruptured aneurysm coiling and 4240 ruptured aneurysm clipping procedures. Declines were observed in aSAH admissions (-6.4% (95% CI-7.0% to-5.8%), p=0.0001) during the first year of the pandemic compared with the prior year, most pronounced in high-volume SAH and high-volume COVID-19 hospitals. There was a trend towards a decline in mild and moderate presentations of subarachnoid haemorrhage (SAH) (mild:-5% (95% CI-5.9% to-4.3%), p=0.06; moderate:-8.3% (95% CI-10.2% to-6.7%), p=0.06) but no difference in higher SAH severity. The ruptured aneurysm clipping rate remained unchanged (30.7% vs 31.2%, p=0.58), whereas ruptured aneurysm coiling increased (53.97% vs 56.5%, p=0.009). There was no difference in aSAH in-hospital mortality rate (19.1% vs 20.1%, p=0.12). Conclusion During the first year of the pandemic, there was a decrease in aSAH admissions volume, driven by a decrease in mild to moderate presentation of aSAH. There was an increase in the ruptured aneurysm coiling rate but neither change in the ruptured aneurysm clipping rate nor change in aSAH in-hospital mortality. Trial registration number NCT04934020.",

author = "Nguyen, {Thanh N.} and Qureshi, {Muhammad M.} and {SVIN Global COVID-19 SAH Registry} and Piers Klein and Hiroshi Yamagami and Robert Mikulik and Nima Etminan and Mohamad Abdalkader and Mansour, {Ossama Yassin} and Anna Czlonkowska and Hannah Lo and Anvitha Sathya and Jelle Demeestere and Georgios Tsivgoulis and Nobuyuki Sakai and Petra Sedova and Kristoffersen, {Espen Saxhaug} and Mahmoud Mohammaden and Lereis, {Virginia Pujol} and Scollo, {Sergio Daniel} and Alice Ma and Aminur Rahman and Thomas Bonnet and Jeroen Cortier and Raedt, {Sylvie De} and Robin Lemmens and Noemie Ligot and Hidalgo, {Raquel C.T.} and Cuervo, {Daissy Liliana Mora} and {De Oliveira Neves}, Luciana and Rezende, {Marco Tulio Salles} and Santiago, {Igor Bessa} and Alexander Sirakov and Stanimir Sirakov and Cora, {Elena Adela} and Kelly, {Michael E.} and Pascale Lavoie and Lissa Peeling and Aleksandra Pikula and Rodrigo Rivera and Chen, {Hui Sheng} and Yimin Chen and Hongliang Fang and Bedekovic, {Marina Roje} and Hrvoje Budincevic and Strossmayer, {J. J.} and Martin {\v C}abal and Emanuela Hrabanovska and Lubomir Jurak and Diederik Dippel and Leon Rinkel",

note = "Funding Information: These coauthors have the following funding: support by STROCZECH within CZECRIN Large Research Infrastructure (number LM2018128) funded by the state budget of the Czech Republic. FNUSA: PS, RM, NCB and JR; lFN Hradec Kr{\'a}lov{\'e}: RH; FESO, FEANNemocnice Jihlava: OS; Hornick{\'a} Nemocnice, a.s.: HP; Nemocnice Liberec: LJ; Nemocnice Na Homolce: MK; Vojensk{\'a} Nemocnice Praha: MS, FP reported royalties from Springer Nature Publishing Group and Elsevier, Research Grant from Transilvania University Brasov, speaker fees and honoraria from International Parkinson and Movement Disorders Society, AbbVie, outside the submitted work. RM was supported by project number CA18118, IRENE COST Action funded by COST Association, by the IRIS-TEPUS project number LTC20051 from the INTER-EXCELLENCE INTER-COST Program of the Ministry of Education, Youth and Sports of the Czech Republic and by STROCZECH within CZECRIN Large Research Infrastructure number LM2018128 funded by the state budget of the Czech Republic. TNN reports research support from Medtronic and the Society of Vascular and Interventional Neurology. RGN reported consulting fees for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Hybernia, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby and Synchron and stock options for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, RapidPulse and Perfuze; and investments in Viz-AI, Perfuze, Cerebrotech, Reist/Q{\textquoteright}Apel Medical, Truvic and Viseon. AP is a consultant for Cerenovus, CereVasc, Merit and Medtronic; received research grants from Medtronic. Stocks in InNeuroCo, Galaxy, Agile, Perfuze and NTI. HY reported research grants from Bristol-Myers Squibb, lecturer{\textquoteright}s fees from Bayer, Daiichi-Sankyo and Stryker, and membership in the advisory boards for Daiichi-Sankyo outside the submitted work. Dr. Siegler reports speakers bureau from AstraZeneca, consulting fees from Ceribell. Funding Information: The study was funded by the Society of Vascular and Interventional Neurology research pilot grant. Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2022",

month = oct,

day = "1",

doi = "10.1136/jnnp-2022-329200",

language = "English",

volume = "93",

pages = "1028--1038",

journal = "Journal of Neurology, Neurosurgery and Psychiatry",

issn = "0022-3050",

publisher = "BMJ Publishing Group",

number = "10",

}

Nguyen, TN, Qureshi, MM, SVIN Global COVID-19 SAH Registry, Klein, P, Yamagami, H, Mikulik, R, Etminan, N, Abdalkader, M, Mansour, OY, Czlonkowska, A, Lo, H, Sathya, A, Demeestere, J, Tsivgoulis, G, Sakai, N, Sedova, P, Kristoffersen, ES, Mohammaden, M, Lereis, VP, Scollo, SD, Ma, A, Rahman, A, Bonnet, T, Cortier, J, Raedt, SD, Lemmens, R, Ligot, N, Hidalgo, RCT, Cuervo, DLM, De Oliveira Neves, L, Rezende, MTS, Santiago, IB, Sirakov, A, Sirakov, S, Cora, EA, Kelly, ME, Lavoie, P, Peeling, L, Pikula, A, Rivera, R, Chen, HS, Chen, Y, Fang, H, Bedekovic, MR, Budincevic, H, Strossmayer, JJ, Čabal, M, Hrabanovska, E, Jurak, L, Dippel, D & Rinkel, L 2022, 'Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up', Journal of Neurology, Neurosurgery and Psychiatry, vol. 93, no. 10, pp. 1028-1038. https://doi.org/10.1136/jnnp-2022-329200

Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up. / Nguyen, Thanh N.; Qureshi, Muhammad M.; SVIN Global COVID-19 SAH Registry et al.
In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 93, No. 10, 01.10.2022, p. 1028-1038.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality

T2 - 1-year follow-up

AU - Nguyen, Thanh N.

AU - Qureshi, Muhammad M.

AU - SVIN Global COVID-19 SAH Registry

AU - Klein, Piers

AU - Yamagami, Hiroshi

AU - Mikulik, Robert

AU - Etminan, Nima

AU - Abdalkader, Mohamad

AU - Mansour, Ossama Yassin

AU - Czlonkowska, Anna

AU - Lo, Hannah

AU - Sathya, Anvitha

AU - Demeestere, Jelle

AU - Tsivgoulis, Georgios

AU - Sakai, Nobuyuki

AU - Sedova, Petra

AU - Kristoffersen, Espen Saxhaug

AU - Mohammaden, Mahmoud

AU - Lereis, Virginia Pujol

AU - Scollo, Sergio Daniel

AU - Ma, Alice

AU - Rahman, Aminur

AU - Bonnet, Thomas

AU - Cortier, Jeroen

AU - Raedt, Sylvie De

AU - Lemmens, Robin

AU - Ligot, Noemie

AU - Hidalgo, Raquel C.T.

AU - Cuervo, Daissy Liliana Mora

AU - De Oliveira Neves, Luciana

AU - Rezende, Marco Tulio Salles

AU - Santiago, Igor Bessa

AU - Sirakov, Alexander

AU - Sirakov, Stanimir

AU - Cora, Elena Adela

AU - Kelly, Michael E.

AU - Lavoie, Pascale

AU - Peeling, Lissa

AU - Pikula, Aleksandra

AU - Rivera, Rodrigo

AU - Chen, Hui Sheng

AU - Chen, Yimin

AU - Fang, Hongliang

AU - Bedekovic, Marina Roje

AU - Budincevic, Hrvoje

AU - Strossmayer, J. J.

AU - Čabal, Martin

AU - Hrabanovska, Emanuela

AU - Jurak, Lubomir

AU - Dippel, Diederik

AU - Rinkel, Leon

N1 - Funding Information: These coauthors have the following funding: support by STROCZECH within CZECRIN Large Research Infrastructure (number LM2018128) funded by the state budget of the Czech Republic. FNUSA: PS, RM, NCB and JR; lFN Hradec Králové: RH; FESO, FEANNemocnice Jihlava: OS; Hornická Nemocnice, a.s.: HP; Nemocnice Liberec: LJ; Nemocnice Na Homolce: MK; Vojenská Nemocnice Praha: MS, FP reported royalties from Springer Nature Publishing Group and Elsevier, Research Grant from Transilvania University Brasov, speaker fees and honoraria from International Parkinson and Movement Disorders Society, AbbVie, outside the submitted work. RM was supported by project number CA18118, IRENE COST Action funded by COST Association, by the IRIS-TEPUS project number LTC20051 from the INTER-EXCELLENCE INTER-COST Program of the Ministry of Education, Youth and Sports of the Czech Republic and by STROCZECH within CZECRIN Large Research Infrastructure number LM2018128 funded by the state budget of the Czech Republic. TNN reports research support from Medtronic and the Society of Vascular and Interventional Neurology. RGN reported consulting fees for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Hybernia, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby and Synchron and stock options for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, RapidPulse and Perfuze; and investments in Viz-AI, Perfuze, Cerebrotech, Reist/Q’Apel Medical, Truvic and Viseon. AP is a consultant for Cerenovus, CereVasc, Merit and Medtronic; received research grants from Medtronic. Stocks in InNeuroCo, Galaxy, Agile, Perfuze and NTI. HY reported research grants from Bristol-Myers Squibb, lecturer’s fees from Bayer, Daiichi-Sankyo and Stryker, and membership in the advisory boards for Daiichi-Sankyo outside the submitted work. Dr. Siegler reports speakers bureau from AstraZeneca, consulting fees from Ceribell. Funding Information: The study was funded by the Society of Vascular and Interventional Neurology research pilot grant. Publisher Copyright: © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2022/10/1

Y1 - 2022/10/1

N2 - Background Prior studies indicated a decrease in the incidences of aneurysmal subarachnoid haemorrhage (aSAH) during the early stages of the COVID-19 pandemic. We evaluated differences in the incidence, severity of aSAH presentation, and ruptured aneurysm treatment modality during the first year of the COVID-19 pandemic compared with the preceding year. Methods We conducted a cross-sectional study including 49 countries and 187 centres. We recorded volumes for COVID-19 hospitalisations, aSAH hospitalisations, Hunt-Hess grade, coiling, clipping and aSAH in-hospital mortality. Diagnoses were identified by International Classification of Diseases, 10th Revision, codes or stroke databases from January 2019 to May 2021. Results Over the study period, there were 16 247 aSAH admissions, 344 491 COVID-19 admissions, 8300 ruptured aneurysm coiling and 4240 ruptured aneurysm clipping procedures. Declines were observed in aSAH admissions (-6.4% (95% CI-7.0% to-5.8%), p=0.0001) during the first year of the pandemic compared with the prior year, most pronounced in high-volume SAH and high-volume COVID-19 hospitals. There was a trend towards a decline in mild and moderate presentations of subarachnoid haemorrhage (SAH) (mild:-5% (95% CI-5.9% to-4.3%), p=0.06; moderate:-8.3% (95% CI-10.2% to-6.7%), p=0.06) but no difference in higher SAH severity. The ruptured aneurysm clipping rate remained unchanged (30.7% vs 31.2%, p=0.58), whereas ruptured aneurysm coiling increased (53.97% vs 56.5%, p=0.009). There was no difference in aSAH in-hospital mortality rate (19.1% vs 20.1%, p=0.12). Conclusion During the first year of the pandemic, there was a decrease in aSAH admissions volume, driven by a decrease in mild to moderate presentation of aSAH. There was an increase in the ruptured aneurysm coiling rate but neither change in the ruptured aneurysm clipping rate nor change in aSAH in-hospital mortality. Trial registration number NCT04934020.

AB - Background Prior studies indicated a decrease in the incidences of aneurysmal subarachnoid haemorrhage (aSAH) during the early stages of the COVID-19 pandemic. We evaluated differences in the incidence, severity of aSAH presentation, and ruptured aneurysm treatment modality during the first year of the COVID-19 pandemic compared with the preceding year. Methods We conducted a cross-sectional study including 49 countries and 187 centres. We recorded volumes for COVID-19 hospitalisations, aSAH hospitalisations, Hunt-Hess grade, coiling, clipping and aSAH in-hospital mortality. Diagnoses were identified by International Classification of Diseases, 10th Revision, codes or stroke databases from January 2019 to May 2021. Results Over the study period, there were 16 247 aSAH admissions, 344 491 COVID-19 admissions, 8300 ruptured aneurysm coiling and 4240 ruptured aneurysm clipping procedures. Declines were observed in aSAH admissions (-6.4% (95% CI-7.0% to-5.8%), p=0.0001) during the first year of the pandemic compared with the prior year, most pronounced in high-volume SAH and high-volume COVID-19 hospitals. There was a trend towards a decline in mild and moderate presentations of subarachnoid haemorrhage (SAH) (mild:-5% (95% CI-5.9% to-4.3%), p=0.06; moderate:-8.3% (95% CI-10.2% to-6.7%), p=0.06) but no difference in higher SAH severity. The ruptured aneurysm clipping rate remained unchanged (30.7% vs 31.2%, p=0.58), whereas ruptured aneurysm coiling increased (53.97% vs 56.5%, p=0.009). There was no difference in aSAH in-hospital mortality rate (19.1% vs 20.1%, p=0.12). Conclusion During the first year of the pandemic, there was a decrease in aSAH admissions volume, driven by a decrease in mild to moderate presentation of aSAH. There was an increase in the ruptured aneurysm coiling rate but neither change in the ruptured aneurysm clipping rate nor change in aSAH in-hospital mortality. Trial registration number NCT04934020.

UR - http://www.scopus.com/inward/record.url?scp=85134306667&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2022-329200

DO - 10.1136/jnnp-2022-329200

M3 - Article

C2 - 35902229

AN - SCOPUS:85134306667

SN - 0022-3050

VL - 93

SP - 1028

EP - 1038

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

IS - 10

ER -

Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this